Rafael Chiong
Internal Medicine · Miami, FLNPI 1487751012
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AbbVie at 49.1% of the total. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 7 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$58
- GSK$33
- Johnson & Johnson$15
- Astellas Pharma US Inc$12
Across 184 payments — averaging $7218.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$699K
- GSK$204K
- Mitsubishi Tanabe Pharma Development America, Inc.$155K
- Cipla USA Inc.$149K
- Endo Pharmaceuticals Inc.$45K
- Sanofi US Services Inc.$28K
- plus $48K from 2 others
What the payments were for
- Food & beverage$117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $58 |
| GSK | 2 | $33 |
| Johnson & Johnson | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$117 in reported general payments places this provider in the 30th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 340 | $193,077 |
| TradjentaLinagliptin | 275 | $137,002 |
| XareltoRivaroxaban | 153 | $82,488 |
| EntrestoSacubitril/Valsartan | 76 | $50,433 |
| FarxigaDapagliflozin Propanediol | 83 | $46,605 |
| MyrbetriqMirabegron | 70 | $30,839 |
| BrilintaTicagrelor | 67 | $28,728 |
| Tadalafil | 148 | $20,914 |
| JardianceEmpagliflozin | 35 | $20,365 |
| VascepaIcosapent Ethyl | 61 | $20,246 |
| LinzessLinaclotide | 39 | $20,207 |
| TrulicityDulaglutide | 21 | $19,659 |
| MultaqDronedarone Hcl | 22 | $16,779 |
| JanuviaSitagliptin Phosphate | 28 | $15,739 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 159 | $14,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $15 | $82,488153 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $30,83970 claims |
| AbbVieLinzess, Synthroid | $58 | $26,168174 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $33 | $18,55936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.